Irish life science technology company Zenith Technologies has appointed Joe Haugh as its Chief Executive Officer (CEO). Haugh will lead the company’s strategic direction and operations, driving ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

The US FDA has accepted priority review of the NDA for Roche’s investigational oral SERD, giredestrant, for breast cancer.

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.

Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.